Co-founded by Stanford researchers, IgGenix is working on therapies that address severe allergies.

IgGenix, a US-based developer of an antibody-based approach to food allergies based on research at Stanford University, has raised $25m in an oversubscribed series A1 round co-led by Khosla Ventures and Matthias Westman. Alexandria Venture Investments, the venture capital unit of life sciences real estate investment trust Alexandria Real Estate Equities, also took part in the round together with ShangBay Capital and AllerFund. Founded in 2019, IgGenix is re-engineering antibodies involves in allergic reactions to alleviate and potentially prevent food and other severe allergies. The cash has been allocated to an expansion of its discovery platform and the acceleration of its lead asset into preclinical development. Khosla Ventures led a $10m series A round in August 2020, when Parker Ventures also participated.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).